Stay updated with breaking news from Beth Brett. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% and liver triglycerides by 67% compared to placebo two months after administration Data also...
BURLINGTON, Mass., May 07, 2024 -- Fractyl Health, Inc. , a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes , today announced...
Fractyl Health Announces Multiple Presentations at DDW 2024 Conference and the German Diabetes Association (DDG) Annual Meeting...
Received IDE approval for the Revita® Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 Based Drugs Completion of enrollment in pivotal...
Revita aims to be the first approved therapeutic option for durable weight maintenance after discontinuation of GLP-1 based drugs, as an adjunct to diet and exercise With this FDA IDE approval,...